Stockscreener 앱 받기
0.984
4.83%
0.0453
시간 외 거래:
.98
-0.004
-0.41%
Akebia Therapeutics Inc 주식(AKBA)의 최신 뉴스
AKBA Shares Rise On Clinical Pipeline Optimism As Anemia Drug Gains Traction - Stocktwits
Akebia Therapeutics sees Vafseo uptake rising as access and pipeline milestones near - MSN
Akebia Strengthens Patent Portfolio with New Grant for Vafseo (A - GuruFocus
Akebia receives new patent, extension eligibility for Vafseo - Investing.com
Akebia receives new patent, extension eligibility for Vafseo By Investing.com - Investing.com South Africa
Akebia Therapeutics Secures New Patent Covering Dosing Regimen for Chronic Kidney Disease - marketscreener.com
Akebia Therapeutics Announces New Patent and Patent Extension Eligibility for Vafseo® (vadadustat) Strengthening Intellectual Property Portfolio - Quiver Quantitative
Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio - GlobeNewswire
Akebia’s Vafseo gains traction as $106B pharma M&A reshapes sector - MSN
Akebia Therapeutics Sees Vafseo Uptake Rising as Access and Pipeline Milestones Near - MarketBeat
AKBA: Vafseo growth accelerates, pipeline advances, and broad access expected post-2026 - TradingView
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
AKBA Stock Price, Quote & Chart | AKEBIA THERAPEUTICS INC (NASDAQ:AKBA) - ChartMill
Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference - The Manila Times
AKBA Q1 2026 Earnings: EPS Misses Estimates Amid Operational DevelopmentsEarnings Cycle Report - thelegaladvocate.com
AKBA Q1 2026 Earnings: EPS Misses Estimates as Stock Holds SteadyEarnings Surprise Stocks - thelegaladvocate.com
Akebia Therapeutics (AKBA) Edges Higher at $1.04 – Key Levels in FocusFair Value Gap - thelegaladvocate.com
Promising Penny Stocks To Consider In May 2026 - Yahoo Finance
Akebia Therapeutics Inc. (AKBA) Q1 2026 Earnings: EPS Misses Estimates Slightly, Stock UnchangedQuarterly Profit Report - thelegaladvocate.com
AKBA Technical Analysis & Stock Price Forecast - Intellectia AI
Akebia Therapeutics (AKBA) Holds Steady at $1.02 as Stock Consolidates Near Key SupportMomentum Stock Picks - newsline.com
Is the options market predicting a spike in Akebia Therapeutics stock? - MSN
Akebia plunges 20% on muted Q1 print - MSN
Number of shareholders of Akebia Therapeutics, Inc. – NASDAQ:AKBA - TradingView
Earnings call transcript: Akebia Therapeutics Q1 2026 reports EPS miss, stock falls - Investing.com Canada
Korsana deal and cash crunch reshape Cyclerion (NASDAQ: CYCN) outlook - Stock Titan
State Street (AKBA) reports 11.6M-share, 4.3% stake in Akebia - Stock Titan
HC Wainwright Issues Negative Estimate for AKBA Earnings - MarketBeat
TradingKey - TradingKey
Akebia outlines phase II FSGS study of up to ~60 patients as Vafseo reaches nearly 7,500 patients - MSN
Here's What Analysts Are Forecasting For Akebia Therapeutics, Inc. (NASDAQ:AKBA) After Its First-Quarter Results - simplywall.st
Analysts Are Updating Their Akebia Therapeutics, Inc. (NASDAQ:AKBA) Estimates After Its First-Quarter Results - Yahoo Finance
Akebia Q1 2026 earnings preview - MSN
HC Wainwright Expects Lower Earnings for Akebia Therapeutics - MarketBeat
Akebia Therapeutics (AKBA) Is Down 14.5% After Swing To Q1 Loss And Share Increase Plan - Sahm
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2026 Earnings Call Transcript - Insider Monkey
Akebia Therapeutics (AKBA) Receives a Buy from H.C. Wainwright - The Globe and Mail
2.11%
자본화:
|
볼륨(24시간):